Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer

Loibl, S., Loirat, D., Tolaney, S. M., Punie, K., Oliveira, M., Rugo, H. S., Bardia, A., Hurvitz, S. A., Brufsky, A. M., Kalinsky, K., Cortés, J., O’Shaughnessy, J. A., Dieras, V., Carey, L. A., Gianni, L., Gharaibeh, M., Preger, L., Phan, S., Chang, L., … Piccart, M. J. (2023). Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. European Journal of Cancer, 178, 23–33. https://doi.org/10.1016/j.ejca.2022.10.003
Authors:
Sibylle Loibl
Thomas Bachelot
Sara M. Tolaney
Kevin Punie
Mafalda Oliveira
Hope S. Rugo
Aditya Bardia
Sara A. Hurvitz
Adam Brufsky
Kevin Kalinsky
Javier Cortés
Joyce O’Shaughnessy
Véronique Dièras
Lisa A. Carey
Luca Gianni
Mahdi Gharaibeh
Luciana Preger
See Phan
Lawrence Chang
Ling Shi
Martine Piccart
Affiliated Authors:
Kevin Kalinsky
Author Keywords:
antibody-drug conjugate
clinical trial
phase iii
eortc qlq-c30
quality of life
sacituzumab govitecan
triple-negative breast neoplasms
antibody–drug conjugate
Publication Type:
Article
Unique ID:
10.1016/j.ejca.2022.10.003
PMID:
Publication Date:
Data Source:
OpenAlex

Record Created: